New

Executive Director, Commercial Operations

Kura Oncology
401(k), stock options
United States, California, San Diego
12730 High Bluff Drive (Show on map)
Feb 01, 2025
Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of. At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics. As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality. To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions. ESSENTIAL JOB FUNCTIONS: In this leadership role, you will be responsible for establishing and leading this critical function to ensure the efficient infrastructure, processes, and technologies necessary for the future successful commercialization of Kura Oncology's portfolio. Oversee field effectiveness and operations, including territory planning, sales performance tracking and analytics, incentive programming, and the development and delivery of customer engagement and sales enablement tools. In collaboration with sales and marketing leadership, lead sales performance reporting and operational reporting Lead team to support the build, implementation, and maintenance of sales tools, including CRM, data analytics, and sales dashboards, in collaboration with commercialization partner as appropriate. Oversee market insights, analytics and competitive intelligence to deliver data driven business recommendations. Lead the strategic development and implementation of databases and infrastructure to support analytics, insights, forecasting and budgeting. Deliver actionable recommendations to the leadership team through analysis, market research, and competitive intelligence. Develop competitive incentive compensation plans that attract, reward, and retain top talent. Collaborate across multiple functions, including Commercial Leadership, Sales, Marketing, Market Access, Medical, Legal, Regulatory, Compliance, Clinical Development and IT. Oversee external vendors and consultants supporting Commercial Operational platforms and resource needs for data analytics, meeting planning, competitive intelligence, IC planning, market research, and other areas as required. Serve as non-voting member of the appropriate commercialization committees with US commercialization partner Kyowa Kirin, ensuring alignment across teams while driving resolution of commercial operation challenges as required. Manage the annual budget for the Commercial Operations organization. Perform other duties as assigned. JOB SPECIFICATIONS: Minimum of 10 years of relevant experience, with a deep understanding of sales, , insights & analytics and operations functions within the pharmaceutical industry. At least 5 years of management experience, leading high-performance teams across diverse functions. Experience working in oncology required, with a strong preference for prior experience in hematology/oncology Excellent verbal, written, and interpersonal skills with the ability to influence senior management and establish effective working relationships with a diverse range of stakeholders. Exceptional skills in proactivity, planning, prioritization, objective setting, meeting management, and plan execution. Exceptional ability to evaluate and analyze a significant amount of data, turning into actionable insights for executive level communication Organized and logical, with a high degree of flexibility to change direction when needed. Self-starter and team player: A confident self-starter who can work independently and creatively, while also being a team player. The base range for an Executive Director is $260,554 - $308,104 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus. Kura's Values that are used for candidate selection and performance assessments: We work as one for patients We are goal-focused and deliver with excellence We are science-driven courageous innovators We strive to bring out the best in each other and ourselves The Kura Package Career advancement/ development opportunities Competitive comp package Bonus 401K + Employer contributions Generous stock options ESPP Plan 20 days of PTO to start 18 Holidays (Including Summer & Winter Break) Generous Benefits Package with a variety of plans available with a substantial employer match Paid Paternity/Maternity Leave In-Office Catered lunches Home Office Setup Lifestyle Spending Stipend Commuter Stipend (Boston Office) Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more! Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company's diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology's approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts. Kura's pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura's website atwww.kuraoncology.comand follow us onXandLinkedIn. Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.